Blistering disorders: Diagnosis and treatment

Dermatologic Therapy

Volumn 16, Issue 3, 2003, Pages 214-223

  Yeh, S W ^a   Ahmed, Babar ^a   Sami, Naveed ^a   Ahmed, A Razzaque ^a,b,c  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b NEW ENGLAND BAPTIST HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Blistering disease; Clinical course; Diagnostic criteria; Pathophysiology; Treatment and management

Indexed keywords

ALUMINUM ACETATE; ALUMINUM SUBACETATE; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CEFTAZIDIME; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DIAMORPHINE; ERYTHROMYCIN; GOLD; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PENICILLAMINE; PENICILLIN G; PERMANGANATE POTASSIUM; PHENYTOIN; PREDNISONE; PROGESTERONE; PYRAZOLE; RIFAMPICIN; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; BLISTER; BONE MARROW SUPPRESSION; BULLOUS SKIN DISEASE; CLINICAL FEATURE; CREAM; DERMATITIS HERPETIFORMIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; EPIDERMOLYSIS BULLOSA ACQUISITA; GEL; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOLOGY; INFECTION; LABORATORY TEST; LINEAR IMMUNOGLOBULIN A DERMATOSIS; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MUCOSA; MUCOUS MEMBRANE PEMPHIGOID; NEPHROTOXICITY; PARANEOPLASTIC SYNDROME; PEMPHIGOID; PEMPHIGUS; PLASMAPHERESIS; PORPHYRIA CUTANEA TARDA; REVIEW; SUBCORNEAL PUSTULAR DERMATOSIS;

DIAGNOSIS, DIFFERENTIAL; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMANS; PARANEOPLASTIC SYNDROMES; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; PEMPHIGOID, BULLOUS; PEMPHIGUS; PORPHYRIA CUTANEA TARDA; SKIN DISEASES; SKIN DISEASES, VESICULOBULLOUS;

EID: 0142057324     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1529-8019.2003.01631.x     Document Type: Review

References (99)

1. Ahmed AR. Clinical features of pemphigus. Clin Dermatol 1983: 1: 13-21.
2. Ahmed AR, Graham J, Jordon RE, Provost TT. Pemphigus: current concepts. Ann Intern Med 1980: 92: 396-405.
3. Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid. Lancet 1999: 354: 667-672.
4. Korman N. Pemphigus. J Am Acad Dermatol 1988: 18: 1219-1238.
5. Becker BA, Gaspari AA. Pemphigus vulgaris and vegetans. Dermatol Clin 1993: 11: 429-452.
6. Simon DG, Krutchkoff D, Kaslow RA, Zarbo R. Pemphigus in Hartford County, Connecticut, from 1972 to 1977. Arch Dermatol 1980: 1169: 1035-1037.
7. Pisant S, Sharav Y, Kaufman E, Posner LN. Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surg Oral Med Oral Pathol 1974: 38: 382-387.
8. Tehranchi-Nia Z, Qureshi TA, Ahmed AR. Pemphigus vulgaris in older adults. J Am Geriatr Soc 1998: 461: 92-94.
9. Sison-Fonacier L, Bystryn JC. Regional variations in the antigenic properties of skin. A possible cause for disease-specific distribution of skin lesions. J Exp Med 1986: 164: 2125-2130.
10. Landau M, Brenner S. Histopathologic findings in drug-induced pemphigus. Am J Dermatopathol 1997:19:411-414.
11. Scott JE, Ahmed AR. The blistering diseases. Med Clin N Am 1998: 82: 1239-1283.
12. Beutner EH, Jordan RE, Chorzaelski TP. The immunopathology of pemphigus and bullous pemphigoid. J Invest Dermatol 1968: 51: 63-68.
13. Beutner EH, Lever WF, Wiebsky E, Jordon R, Chertock B. Autoantibodies in pemphigus vulgaris. J Am Acad Dermatol 1965: 8: 682-688.
14. Beutner EH, Rhodes EL, Holborow EJ. Autoimmunity in chronic bullous skin diseases. Immunofluorescent demonstration of three types of antibodies to skin in sera of patients with pemphigus, bullous pemphigoid and in other human sera. Clin Exp Immunol 1967: 2: 141-151.
15. Weissman V, Feuerman EJ, Joshua H, Hazaz B. The correlation between the antibody titers in sera of patients with pemphigus vulgaris and their clinical state. J Invest Dermatol 1978: 71: 107-109.
16. Amagai M. Autoimmunity against desmosomal cadherins in pemphigus. J Dermatol Sci 1999: 20: 92-102.
17. Amagai M, Komai A, Hashimoto T, et al. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 1999: 140: 351-357.
18. Hashimoto T, Amagai M, Garrod DR, Nishikawa T. Immunofluorescence and immunoblot studies on the reactivity of pemphigus vulgaris and pemphigus foliaceus sera with desmoglein 3 and desmoglein 1. Epithelial Cell Biol 1995: 4: 63-69.
19. Ahmed AR, Sami N. Uncommon manifestations of pemphigus vulgaris. J Eur Acad Dermatol Venereol 2002: 16: 313-315.
20. Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol 1996: 34: 645-652.
21. Lever WF, Schumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol 1977: 113: 1236-1241.
22. Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol 1993: 28: 998-1000.
23. Piamphongsant T. Pemphigus controlled by dapsone. Br J Dermatol 1976: 94: 681-686.
24. Krain LS, Landau JW, Newcomer VD. Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid. Arch Dermatol 1972: 106: 657-661.
25. Ebringer A, Mackay IR. Pemphigus vulgaris successfully treated with cyclophosphamide. Ann Intern Med 1969: 71: 125-127.
26. Thivolet J, Barthelemy H, Rigo-Muller G, Bendelac A. Effects of cyclosporine on bullous pemphigoid and pemphigus. Lancet 1985: 1: 334-335.
27. Lapidoth M, David M, Ben-Amitai D, Katzenelson V, Lustig S, Sandbank M. The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study. J Am Acad Dermatol 1994: 30: 752-757.
28. Penneys NS, Eaglstein WH, Indgin S, Frost P. Gold sodium thiomalate treatment of pemphigus. Arch Dermatol 1973: 108: 56-60.
29. Shah N, Green AR, Elgart GW, Kerdel F. The use of chlorambucil with prednisone in the treatment of pemphigus. J Am Acad Dermatol 2000: 42: 85-88.
30. Enk AH, Knop J. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 1997: 350: 494.
31. Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol 1996: 132: 1435-1439.
32. Jablonska S, Chorzelski T, Blaszczyk M. Immunosuppressants in the treatment of pemphigus. Br J Dermatol 1970: 84: 315-323.
33. Otley CC. Immunosuppression and skin cancer. Pathogenic insights, therapeutic challenges, and opportunities of innovation. Arch Dermatol 2002: 138: 827-828.
34. Dutz JP, Ho VC. Immunosuppressive agents in dermatology. An update. Dermatol Clin 1998: 16: 235-251.
35. Pandya AG, Sontheimer RD. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide. Arch Dermatol 1992: 128: 1626-1630.
36. Rook AH, Heald PW, Nahass GT, et al. Treatment of autoimmune disease with extracorporeal photochemotherapy: pemphigus vulgaris - preliminary report. Yale J Biol Med 1989: 62: 647-652.
37. Fine JD, Appell ML, Green LK, Sams WM Jr. Pemphigus vulgaris. Combined treatment with intravenous corticosteroid pulse therapy, plasmapheresis, and azathioprine. Arch Dermatol 1988: 124: 236-239.
38. Toth GG, van der Meer JB, Jonkman MF. Dexamethasone pulse therapy in pemphigus. J Eur Acad Dermatol 2002: 16: 562-563.
39. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001: 45: 679-690.
40. Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002: 138: 1158-1162.
41. Sami N, Bhol K, Ahmed AR. Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up, and treatment responses. Clin Exp Immunol 2001: 125: 492-498.
42. Ahmed AR, Sami N. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J Am Acad Dermatol 2002: 46: 42-49.
43. Sami N, Qureshi A, Ahmed AR. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus. Eur J Dermatol 2002: 12: 174-178.
44. Williams LC, Nesbitt LT. Update on systemic glucocorticosteroids in dermatology. Dermatol Clin 2002: 19: 63-77.
45. Nguyen VT, Ndoye A, Bassler KD, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol 2001: 137: 193-206.
46. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus: an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990: 323: 1729-1735.
47. Stevens SR, Griffiths CEM, Anhalt GJ, et al. Paraneoplastic pemphigus presenting as a lichen planus pemphigoides-like eruption. Arch Dermatol 1993: 129: 866-869.
48. Oursler J, Ariss-Abdo L, Labib RS, et al. Human autoantibodies against desmoplakins in paraneoplastic pemphigus. J Clin Invest 1992: 89: 1775-1782.
49. Joly P, Thomine E, Gilbert D, et al. Overlapping distribution of autoantibody specificities in paraneoplastic pemphigus and pemphigus vulgaris. J Invest Dermatol 1994: 103: 65-72.
50. Yancey KB, Egan CA. Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations. JAMA 2000: 284: 350-356.
51. Zillikens D, Wever S, Hashimoto T, Brocker EB. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol 1995: 131: 957-958.
52. Bernard PP, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Disease French Study Group. Arch Dermatol 1995: 131: 48-52.
53. Jordan RE, Beutner EH, Witebsky E, Blumenthal G, Hale WL, Lever WF. Basement zone antibodies in bullous pemphigoid. JAMA 1967: 200: 751-756.
54. Gammon WR, Briggaman RA, Inman AO III, Queen LL, Wheeler CE. Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. J Invest Dermatol 1984: 82: 139-144.
55. Ghoestani RF, Nicolas JF, Rousselle P, Claudy AL. Diagnostic value of indirect immunofluorescence on sodium chloride-split skin in differential diagnosis of subepidermal autoimmune bullous dermatoses. Arch Dermatol 1997: 133: 1102-1107.
56. Schmidt E, Obe K, Brocker EB, Zillikens D. Serum levels of autoantibodies to BP 180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000: 136: 174-178.
57. Amo Y, Ohkawa T, Tatsuta M, et al. Clinical significance of enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci 2001: 26: 14-18.
58. Sami N, Ali S, Bhol K, Ahmed AR. Influence of IVIg on autoantibody titers to BP Ag1 and BP Ag2 in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol (in press).
59. Khumalo NP, Murrell DF, Wojnarowska F, Kirtschig G. A systematic review of treatments for bullous pemphigoid. Arch Dermatol 2002: 138: 385-389.
60. Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001: 45: 825-835.
61. Wojnarowska F, Kirtschig G, Highet AS, Venning VA, Khumalo NP. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002: 147: 214-221.
62. Piamphongsant T, Ausawamongkonpan S. Bullous pemphigoid controlled by dapsone. Dermatologica 1976: 152: 352-357.
63. Person JR, Rogers RS III. Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch Dermatol 1977: 113: 610-615.
64. Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report. Arch Dermatol 1986: 122: 670-674.
65. Greaves MW, Burton JL, Marks J, Dawber RP. Azathioprine in the treatment of bullous pemphigoid. Br Med J 1971: 1: 144-145.
66. Milligan A, Hutchinson PE. The use of chlorambucil in the treatment of bullous pemphigoid. J Am Acad Dermatol 1990: 22: 796-801.
67. Bohm M, Beissert S, Schwarz T, Metze D, Luger T. Bullous pemphigoid treated with mycophenolate mofetil. Lancet 1997: 349: 541.
68. Dawe RS, Naidoo DK, Ferguson J. Severe bullous pemphigoid responsive to pulsed intravenous dexamethasone and oral cyclophosphamide. Br J Dermatol 1997: 137: 826-827.
69. Itoh T, Hosokawa H, Shirai Y, Horio T. Successful treatment of bullous pemphigoid with pulse intravenous cyclophosphamide. Br J Dermatol 1996: 134: 931-933.
70. Siegel J, Eaglstein WH. High-dose methylprednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1984: 120: 1157-1165.
71. Goldberg NS, Robinson JK, Roenigk HH Jr, Marder R, Rothe M. Plasmapheresis therapy for bullous pemphigoid. Arch Dermatol 1985: 121: 1484-1485.
72. Ahmed AR, Kurgis BS, Rogers RS III. Cicatricial pemphigoid. J Am Acad Dermatol 1991: 24: 987-1001.
73. Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol 2000: 43: 571-591.
74. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002: 138: 370-379.
75. Egan CA, Lazaroven Z, Darling TN, Yee C, Cote T, Yancey KB. Anti-epilgrin cicatricial pemphigoid and relative risk of cancer. Lancet 2001: 357: 1850-1851.
76. Rogers RS III, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 1982: 6: 215-223.
77. Rogers RS III, Mehregan DA. Dapsone therapy of cicatricial pemphigoid. Semin Dermatol 1988: 7: 201-205.
78. Van Der Wal BV, Jonkman MF. Topical treatment with tetracycline in a patient with cicatricial pemphigoid. J Am Acad Dermatol 1997: 36: 492-493.
79. Burton JL, Harman RMM, Peachey RDG, Waring RP. Azathioprine plus prednisone in the treatment of pemphigoid. Br Med J 1978: 2: 1190-1191.
80. Miserocchi E, Baltatzis S, Roque MR, Ahmed AR, Foster CS. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology 2002: 109: 111-118.
81. Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 1999: 106: 2136-2143.
82. Sami N, Bhol KC, Ahmed AR. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol 2002: 102: 59-67.
83. Gammon WR, Briggaman RA, Woodley DT, Heald PW, Wheeler CE Jr. Epidermolysis bullosa acquisita - a pemphigoid-like disease. J Am Acad Dermatol 1984: 11: 820-832.
84. Gammon WR. Epidermolysis bullosa acquisita. Semin Dermatol 1988: 7: 218-224.
85. Gammon WR, Briggaman RA, Inman AO, Queen LL, Wheeler CE. Differentiating anti-lamina lucida and antisublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. J Invest Dermatol 1984: 82: 139-144.
86. Woodley DT, Briggaman RA, O'Keefe EJ, Inman AO, Queen LL, Gammon WR. Identification of the skin basement membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 1984: 310: 1007-1013.
87. Engineer L, Ahmed AR. Emerging treatment for epidermolysis bullosa acquisita. J Am Acad Dermatol 2001: 44: 818-828.
88. Wojnarowska F. What's new in linear IgA disease? J Eur Acad Dermatol Venereol 2000: 14: 441-443.
89. Richards SS, Hall S, Yokel B, et al. A bullous eruption in an elderly woman: vancomycin associated linear IgA dermatosis. Arch Dermatol 1995: 13: 1450-1451.
90. Marinkovich MP, Taylor TB, Keene DR, et al. LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel anchoring filament protein synthesized by epidermal cells. J Invest Dermatol 1996: 106: 734-738.
91. Sachs JS, Leonard J, Awad J, et al. A comparative serological and molecular study of linear IgA disease and dermatitis herpetiformis. Br J Dermatol 1988: 118: 759-764.
92. Chaffins M, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol 1993: 28: 998-999.
93. Letko E, Bhol K, Foster CS, Ahmed AR. Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy. Ophthalmology 2000: 107: 1524-1528.
94. Khan IU, Bhol KC, Ahmed AR. Linear IgA bullous dermatosis in patients with chronic renal failure: a response to IVIg. J Am Acad Dermatol 1999: 40: 485-488.
95. Lamkin BC, Bickers DR. Porphyria cutanea tarda: a metabolic human blistering disease. Dermatol Clin 1983: 1: 249-262.
96. Grossman ME, Pho-Fitzpatrick MB. Porphyria cutanea tarda: diagnosis, management, and differentiation from other hepatic porphyries. Dermatol Clin 1986: 4: 297-309.
97. Cormane RH, Szabo E, Hoo TT. Histopathology of the skin in acquired and hereditary porphyria cutanea tarda. Br J Dermatol 1971: 85: 531-539.
98. Sneddon IB, Wilkinson DS. Subcorneal pustular dermatosis. Br J Dermatol 1956: 68: 385-394.
99. Wilkinson DS. Pustular dermatoses. Br J Dermatol 1969: 81(suppl 3): 38-45.